# A Study of the Efficacy and Safety of Rituximab in Participants With Systemic Sclerosis

> **NCT04274257** · PHASE2,PHASE3 · COMPLETED · sponsor: **Tokyo University** · enrollment: 56 (actual)

## Conditions studied

- Scleroderma, Systemic
- Skin Sclerosis
- Lung Fibrosis
- Autoimmune Diseases
- Collagen Diseases

## Interventions

- **DRUG:** Double-Blind Placebo
- **DRUG:** Double-Blind Rituximab

## Key facts

- **NCT ID:** NCT04274257
- **Lead sponsor:** Tokyo University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-04
- **Primary completion:** 2019-05-09
- **Final completion:** 2019-11-05
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2020-02-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04274257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04274257, "A Study of the Efficacy and Safety of Rituximab in Participants With Systemic Sclerosis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04274257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*